Search
Benazepril
go.drugbank.com/drugs/DB00542ApprovedInvestigationalUpon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor[A836]. … Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure[A838,A837].
Categories: Agents Acting on the Renin-Angiotensin System, Antihypertensive Agents Indicated for HypertensionLatanoprostene bunod
go.drugbank.com/drugs/DB11660ApprovedThe novelty of this agent subsequently lies in the proposed dual mechanism of action that stems from both its prostaglandin F2-alpha analog latanoprost acid metabolite and its ability to donate NO for … Conversely however, latanoprostene bunod integrates an NO-donating moiety in lieu of the isopropyl ester typically found in latanoprost.
Dexmethylphenidate
go.drugbank.com/drugs/DB06701ApprovedInvestigationalDexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002[A177181]. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193]. … It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181].
Categories: Psychostimulants, Agents Used for ADHD and Nootropics, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: methyl (R)-phenyl[(R)-piperidin-2-yl]acetateStromal cell-derived factor 1
go.drugbank.com/bio_entities/BE0001150TargetHumansHas several critical functions during embryonic development; required for B-cell lymphopoiesis, myelopoiesis in bone marrow and heart ventricular septum formation (By similarity). … Induces down-regulation and internalization of ACKR3 expressed in various cells.
Synonyms: Intercrine reduced in hepatomasPanobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. … The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted
Synonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-Larotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigationalIt was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805] … [L49821] Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors.
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763] … Tiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid].
Categories: Drugs for Treatment of Bone DiseasesSimeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnor second-line threapies for treatment-naïve patients as adjunct to sofosbuvir treatment for genotype 1 or PEG-Interferon/ribavirin combination therapy for genotype 1 or 4. … In patients with HCV genotype 1 with compensated cirrhosis, the treatment is directed for 24 week duration.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseBordetella pertussis fimbriae 2/3 antigen
go.drugbank.com/drugs/DB10790ApprovedInvestigationalBordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct
Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, , Suspension for InjectionBerotralstat
go.drugbank.com/drugs/DB15982ApprovedInvestigational[L41960] In December 2025, the FDA expanded Berotralstat pediatric use with approval of an oral pellet formulation for prophylaxis in children with HAE aged 2 and older.[L54793,L54798] … [A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older.
Synonyms: 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide, (R)-1-(3-(aminomethyl) phenyl)-N-(5-((3- cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3- (trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochlorideCategories: Drugs Used in Hereditary Angioedema